Trial Profile

Safety and efficacy of OPGx-MERTK in patients with Retinitis pigmentosa

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPGx MERTK (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions

Most Recent Events

12 Feb 2026 New trial record
27 Jan 2026 According to an Opus Genetics media release,the Opus MERTK program is expected to commence clinical development activities in 2026.
27 Jan 2026 According to an Opus Genetics media release, the company announced the launch and funding of its clinical trial evaluating a gene therapy for MERTK-related retinitis pigmentosa (RP). Cleveland Clinic Abu Dhabi will serve as the clinical site.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com